Niagen Bioscience Reports Q2 2026 Financial Results with Decreased Revenue and Net Income

Niagen Bioscience, Inc. reported its financial results for the second quarter of 2026, revealing a net income of $963,000, or $0.01 per share, compared to $3.6 million, or $0.05 per share, in the same period last year. For the first half of 2026, the company generated a net income of $7.3 million, down from $8.7 million in the prior year. Total revenue for the second quarter was $29.8 million, a decrease of 4% from $31.1 million in the same quarter of 2025. Year-to-date revenue also saw a slight decline, totaling $61.3 million compared to $61.6 million in the first half of 2025.

The decline in revenue was primarily attributed to a significant drop in the Ingredients segment, which saw a 29% decrease in sales compared to the previous year. This was partially offset by a 6% increase in the Consumer Products segment, driven by strong sales of the company's flagship product, Tru Niagen®. The company noted that e-commerce sales were particularly strong, contributing to a $1.5 million increase in sales for the quarter. However, sales to a major customer, A.S. Watson Group, decreased significantly, impacting overall performance.

In terms of operational changes, Niagen Bioscience completed the sale of its Analytical Reference Standards and Services segment in February 2026 for approximately $6 million, which resulted in a gain of $4.8 million recognized in the first quarter. This divestiture allows the company to focus more on its core consumer products and ingredient supply businesses. The transition services agreement related to this sale generated $236,000 in revenue during the second quarter, although this is expected to be temporary.

The company’s total assets as of June 30, 2026, stood at $106.6 million, slightly up from $106.4 million at the end of 2025. Current liabilities decreased significantly to $15.1 million from $19.9 million, primarily due to reductions in accounts payable and accrued expenses. Niagen Bioscience ended the quarter with $66.7 million in cash and cash equivalents, which the company believes will be sufficient to meet its financial obligations over the next twelve months.

Looking ahead, Niagen Bioscience is optimistic about its growth prospects, particularly with the recent launch of its telehealth platform, Niagen Plus, which allows patients to access prescription-based Niagen® products. The company is also advancing its pharmaceutical development efforts, including the recent introduction of NB4168, a candidate for treating Ataxia-Telangiectasia, which has received designations from both the FDA and EMA. Despite the challenges faced in the first half of 2026, the company remains focused on expanding its market presence and enhancing its product offerings.